Gonococcal antimicrobial susceptibility surveillance in Europe, 2014

surveillance report external quality assessment
Publication series: Gonococcal antimicrobial susceptibility surveillance in Europe
Time period covered: 2014
Cite:
Citation Link

European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe, 2014. Stockholm: ECDC; 2016.

Copy citation to clipboard

​The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC) since 2009. This surveillance is essential for detecting emerging and increasing antimicrobial resistance and making quality-assured data available to inform revisions of treatment guidelines. 

In 2014, 23 EU/EEA Member States participated in European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP). Participating laboratories were asked to collect gonococcal isolates during the period September–November. Laboratories participated through centralised or decentralised testing. Decentralised testing took place on the premises of participating laboratories fulfilling set quality criteria. A total of 2 151 isolates were collected and tested for susceptibility to the antimicrobials cefixime, ceftriaxone, ciprofloxacin and azithromycin.​

Executive summary